Authors' objectives: Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Follicular lymphoma is the second most common type of non-Hodgkin lymphoma. It often progresses slowly, with patients showing no symptoms for many years. Nivolumab is a new antibody drug for the treatment of follicular lymphoma that is delivered straight into the bloodstream via a drip. Some studies have suggested that this drug may be helpful for people with follicular lymphoma whose disease has returned after previous treatments have stopped working. If nivolumab is licensed for use in the UK, it could be a new treatment option for follicular lymphoma that may improve survival.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/nivolumab-for-follicular-non-hodgkin-lymphoma-third-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)